SurgiMab: Using Antibodies to Improve Oncology Surgery

ARTICLE SUMMARY:

SurgiMab’s fluorescence-labeled antibodies will enable surgeons to find otherwise undetectable malignancies, allowing them to remove cancers they might have previously missed, and spare healthy tissue. By Deborah Erickson.

“There is more here than meets the eye.” Sadly, this common phrase often proves all too true when it comes to cancer. Surgeons do their best to remove cancerous tissue, even allowing some extra margin when possible to be sure they get it all. But the reality is, they can’t take what they can’t see.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: